文献速递白血病

急性髓系白血病不同性别的治疗结局分析

[Analysis of treatment outcomes of acute myeloid leukemia between different genders].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

男性携带更多髓系基因突变及不良染色体异常,1个疗程CR/CRi率更低,RFS和OS更差。

要点

  • 男性AML患者携带ASXL1、U2AF1、SRSF2等髓系基因突变及-7/7q-、+8比例更高。
  • 男性与更低1个疗程CR/CRi率(OR=0.80)及更差RFS(HR=1.17)和OS(HR=1.27)独立相关。
  • 接受阿扎胞苷联合维奈克拉方案男性1个疗程CR/CRi率更低(62%对73%,P=0.004)。

核心结论

  • 在AML患者中,男性较女性携带预后不良的基因突变和染色体异常比例更高,性别间治疗反应率和OS率存在差异。

主要发现

  • 男性血红蛋白、尿酸、白蛋白水平更高,估算肾小球滤过率更低(白蛋白P=0.006,余均P<0.001)。
  • 男性携带髓系基因突变个数更多(P=0.001),ASXL1、U2AF1、SRSF2、RUNX1、ZRSR2、DDX41、SETBP1、TET2和FLT3-TKD突变及-7/7q-和+8比例更高,NPM1、DNMT3A和FLT3-ITD突变比例更低(均P<0.05)。
  • 多因素分析显示男性与更低1个疗程CR/CRi率(OR=0.80,95%CI:0.66~0.97,P=0.023)、更低RFS(HR=1.17,95%CI:1.00~1.37,P=0.046)和OS(HR=1.27,95%CI:1.09~1.47,P=0.002)显著相关。
  • ELN 2022预后良好、中等和不良患者中,均可见男性较女性OS率更低。
  • 接受阿扎胞苷联合维奈克拉方案男性1个疗程CR/CRi率更低(62%对73%,P=0.004),强化疗组(70%对71%,P=0.593)和CAG组(54%对62%,P=0.222)差异无统计学意义。

关键数值与推荐

  • 男性与更低1个疗程CR/CRi率相关(OR=0.80,95%CI:0.66~0.97,P=0.023)。
  • 男性与更低RFS相关(HR=1.17,95%CI:1.00~1.37,P=0.046)。
  • 男性与更低OS相关(HR=1.27,95%CI:1.09~1.47,P=0.002)。
  • 阿扎胞苷联合维奈克拉方案男性1个疗程CR/CRi率62%对女性73%(P=0.004)。
  • 首次CR期移植组男性4年OS率74%(95%CI:69%~78%)对女性81%(95%CI:77%~85%)(P=0.007)。

临床怎么用

  • 临床评估AML预后时应关注性别差异,男性患者可能具有更高不良遗传学风险和治疗反应劣势。
  • 接受阿扎胞苷联合维奈克拉方案的男性患者需警惕较低1个疗程CR/CRi率,加强疗效监测。
  • 移植后男性患者4年OS率低于女性,提示需优化移植后管理策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To compare the treatment outcomes between male and female patients with acute myeloid leukemia (AML) . Methods: In this retrospective cohort study, data from adult patients with newly diagnosed AML at Peking University People's Hospital between January 2017 and June 2025 were collected and analyzed. The primary outcomes included complete remission with or without incomplete hematological recovery (CR/CRi) and overall survival (OS) rate. Results: A total of 2 264 patients were enrolled, including 1 180 males (52%). Males had significantly higher hemoglobin, uric acid, and albumin levels, but a lower estimated glomerular filtration rate than females (P=0.006 for albumin, P<0.001 for other variables). Males harbored a greater number of myeloid gene mutations (P=0.001) and showed significantly higher frequencies of ASXL1, U2AF1, SRSF2, RUNX1, ZRSR2, DDX41, SETBP1, TET2, and FLT3-TKD mutations, as well as -7/7q- and +8 chromosomal abnormalities. Contrarily, males exhibited significantly lower frequencies of NPM1, DNMT3A, and FLT3-ITD mutations than females. Multivariate analysis showed that male sex was significantly associated with a lower rate of CR/CRi after one course of induction therapy (OR=0.80, 95% CI: 0.66-0.97, P=0.023) and inferior relapse-free survival (HR=1.17, 95% CI: 1.00-1.37, P=0.046) and OS (HR=1.27, 95% CI: 1.09-1.47, P=0.002). Among patients classified as having favorable-, intermediate-, or adverse-risk disease according to ELN 2022 risk classification, males had inferior OS compared with females. In patients receiving the azacitidine plus venetoclax regimen, males had a significantly lower CR/CRi rate after one treatment course (62% vs 73%, P=0.004), but the difference was not significant in those receiving intensive chemotherapy (70% vs 71%, P=0.593) or the CAG regimen (54% vs 62%, P=0.222). Among patients who achieved CR/CRi, the 4-year OS rate was significantly lower in males than in females in both the allogeneic hematopoietic stem cell transplantation (allo-HSCT) group with CR1 [74% (95% CI: 69%-78%) vs 81% (95% CI: 77%-85%), P=0.007] and allo-HSCT group with CR2 or no response [54% (95% CI: 43%-66%) vs 69% (95% CI: 58%-80%), P=0.035]. In the non-transplant group, males showed a trend toward inferior 4-year OS rate[55% (95% CI: 49%-60%) vs 59% (95% CI: 54%-64%), P=0.084]. Conclusion: In patients with AML, males are more likely to harbor myelodysplasia-related gene mutations and chromosomal abnormalities, and sex-based disparities in the treatment response and OS rates have also been observed. 目的: 比较急性髓系白血病(AML)患者中男性和女性的治疗结局。 方法: 本研究为回顾性队列研究。收集2017年1月至2025年6月在北京大学人民医院新诊断的成人AML患者的数据。主要观察终点包括完全缓解伴或不伴血液学恢复(CR/CRi)率和总生存(OS)率。 结果: 纳入2 264例患者,1 180例(52%)为男性。男性的血红蛋白、尿酸、白蛋白水平比女性更高,估算肾小球滤过率更低(白蛋白P=0.006,余均P<0.001)。男性携带髓系基因突变的个数比女性更多(P=0.001),且携带ASXL1、U2AF1、SRSF2、RUNX1、ZRSR2、DDX41、SETBP1、TET2和FLT3-TKD突变,以及-7/7q-和+8的比例较女性更高,携带NPM1、DNMT3A和FLT3-ITD突变的比例更低,差异均有统计学意义(均P<0.05)。多因素分析显示,男性与更低的1个疗程CR/CRi率(OR=0.80,95%CI:0.66~0.97,P=0.023),以及更低的无复发生存(RFS)率(HR=1.17,95%CI:1.00~1.37,P=0.046)和OS率(HR=1.27,95%CI:1.09~1.47,P=0.002)显著相关。欧洲白血病网(ELN)2022预后良好、中等和不良的患者中,均可见男性较女性的OS率更低。接受阿扎胞苷联合维奈克拉方案的男性患者1个疗程CR/CRi率更低(62%对73%,P=0.004),强化疗组(70%对71%,P=0.593)和CAG组(54%对62%,P=0.222)男女患者的1个疗程CR/CRi率差异均无统计学意义。在获得CR/CRi的患者中,男性4年OS率在首次CR期异基因造血干细胞移植组[74%(95%CI:69%~78%)对81%(95%CI:77%~85%),P=0.007]和第2次CR或未达CR/CRi移植组[54%(95% CI:43%~66%)对69%(95% CI:58%~80%),P=0.035]均低于女性;未移植组男性的4年OS率有低于女性的趋势[55%(95% CI:49%~60%)对59%(95% CI:54%~64%),P=0.084]。 结论: 在AML患者中,男性较女性携带预后不良的基因突变和染色体异常比例更高;性别间治疗反应率和OS率存在差异。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Li ZR, Yu L, Hu LJ, et al. [Analysis of treatment outcomes of acute myeloid leukemia between different genders]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42851174. doi:10.3760/cma.j.cn121090-20260312-00129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。